Journey Medical (DERM) vs NervGen Pharma (NGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Journey Medical (DERM) has outperformed NervGen Pharma (NGEN) over the past year, losing 20.9% versus a loss of 48.2%. NervGen Pharma is the larger company by market cap ($186.4 million vs $175.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DERM | NGEN |
|---|---|---|
| Share price | $6.23 | $1.73 |
| Market cap | $175.84M | $186.36M |
| 1-day change | +4.71% | -0.96% |
| YTD return | -22.83% | -68.75% |
| 1-year return | -20.88% | -48.18% |
| 5-year return | — | -7.41% |
| EPS (TTM) | $-0.22 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.56 | $6.30 |
| 52-week low | $4.31 | $1.58 |
| Distance from 52-week high | -34.80% | -72.49% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +120.71% | +476.97% |
| Average volume | 184.01K | 565.19K |
| Shares outstanding | 22.22M | 107.52M |
| Employees | 58 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DERM has outperformed NGEN by 27.3 percentage points over the past year.
About Journey Medical
DERM stock →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
About NervGen Pharma
NGEN stock →NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
DERM vs NGEN FAQ
Which is bigger, Journey Medical or NervGen Pharma?
NervGen Pharma (NGEN) is larger, with a market capitalization of $186.36M compared with $175.84M for Journey Medical (DERM).
Which stock has performed better over the past year, DERM or NGEN?
DERM returned -20.88% over the past 12 months, compared with -48.18% for NGEN (price return, excluding dividends). Past performance does not predict future results.
Are Journey Medical and NervGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.